Lung Biotechnology PBC clinical trials

A subsidiary of United Therapeutics

The registry lists 8 studies whose lead sponsor is Lung Biotechnology PBC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 30, 2020.

Studies

Recruiting first, then most recently updated. Showing 8 of 8. All United Therapeutics studies →

• Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)CompletedNCT00989963Phase 2

  Sponsor listed in the registry: Lung Biotechnology PBC

• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial HypertensionTerminatedNCT03657095Phase 3

  Sponsor listed in the registry: Lung Biotechnology PBC

• Beraprost-314d Added-on to Tyvaso® (BEAT)CompletedNCT01908699Phase 3

  Sponsor listed in the registry: Lung Biotechnology PBC

• A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH PatientsCompletedNCT00781885Phase 2

  Sponsor listed in the registry: Lung Biotechnology PBC

• An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00792571Phase 2

  Sponsor listed in the registry: Lung Biotechnology PBC

• Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) PatientsCompletedNCT00990314Phase 2

  Sponsor listed in the registry: Lung Biotechnology PBC

• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00703339Phase 2

  Sponsor listed in the registry: Lung Biotechnology PBC

• A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 InhibitorWithdrawnNCT01458236Phase 3

  Sponsor listed in the registry: Lung Biotechnology PBC